ReviewCureus2024
Gut-Brain Axis: Unveiling the Interplay Between Diabetes Mellitus and Alzheimer's Disease.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The Interaction Between Insulin Resistance and Neuroinflammation in the Brain and Its Impact on Diabetic Encephalopathy.Biology · 2026Review
- Insulin Resistance and Inflammation.International journal of molecular sciences · 2026Review
- Targeting the astrocytic metabolic cascade in Alzheimer's disease: mechanisms, challenges and opportunities.Frontiers in aging neuroscience · 2026Review
- Dietary Geranylgeraniol Mitigates Pain-Associated Behaviors via Improving Mitochondrial Function and Colon Integrity and Suppressing Neuroinflammation in Male Diabetic Neuropathy Rats.International journal of molecular sciences · 2025Article
- Opposite causal effects of type 2 diabetes and metformin on Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- A review of type 2 diabetes mellitus and cognitive impairment.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut-brain axis (GBA) represents a complex bidirectional communication system linking the gastrointestinal tract with the CNS, influencing various physiological processes, including cognition. Emerging research suggests a significant interplay between diabetes mellitus (DM) and Alzheimer's disease (AD) mediated through this axis. DM, characterized by impaired insulin signaling and chronic inflammation, appears to exacerbate the pathology of AD. Key mechanisms include insulin resistance affecting neuronal function and promoting amyloid-beta accumulation and tau phosphorylation, hallmark features of AD. Additionally, dysbiosis of gut microbiota in DM may contribute to neuroinflammation and oxidative stress, further aggravating AD pathology. The gut microbiota can modulate systemic inflammation and metabolic dysfunction, potentially impacting AD progression in DM individuals. Understanding these interactions is crucial for developing targeted therapeutic strategies that address both DM and AD simultaneously. This abstract highlights the intricate relationship between metabolic disorders like DM and neurodegenerative conditions such as AD, emphasizing the role of the GBA as a pivotal area for future research and therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.